GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab
Phase 1/2
365
about 4.5 years
18+
13 sites in CA, CO, CT +9
What this study is about
Researchers are testing GV20-0251, either alone or with pembrolizumab, as a treatment for adults with advanced solid tumors that have not responded to other treatments. The trial will last about 1627 days and involve approximately 365 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive GV20-0251
- 2.Receive GV20-0251 and Pembrolizumab [KEYTRUDA®]
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Objective Response Rate ORR per RECIST version 1.1 (Parts B and D), Percentage of Participants With Adverse Events (Parts A and C)
Secondary: AUC, Additional safety and tolerability, Cmax of GV20-0251, DCR, DoR, ORR (Parts A and C), Overall Survival (Parts B and D), PFS
Oncology, Gastroenterology